loading
Schlusskurs vom Vortag:
$11.66
Offen:
$11.66
24-Stunden-Volumen:
121.11K
Relative Volume:
0.61
Marktkapitalisierung:
$563.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.94%
1M Leistung:
-1.98%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$11.47
$12.25
1-Wochen-Bereich:
Value
$11.13
$13.47
52-Wochen-Spanne:
Value
$6.71
$16.09

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name
Firmenname
Maze Therapeutics Inc
Name
Telefon
(650) 850-5070
Name
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Name
Mitarbeiter
125
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
MAZE's Discussions on Twitter

Vergleichen Sie MAZE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MAZE
Maze Therapeutics Inc
11.86 563.67M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten

pulisher
May 29, 2025

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewswire

May 29, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 21, 2025

Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail

May 21, 2025
pulisher
May 19, 2025

Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position - TipRanks

May 19, 2025
pulisher
May 18, 2025

Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World

May 18, 2025
pulisher
May 16, 2025

Contrasting Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE) - Defense World

May 16, 2025
pulisher
May 14, 2025

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Maze Therapeutics Q1 Earnings: Dual Clinical Programs Progress as Cash Position Hits $294M - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Maze Therapeutics CEO to Present Company Overview at 3rd Annual H.C. Wainwright BioConnect Investor Conference - Nasdaq

May 13, 2025
pulisher
May 01, 2025

Maze Therapeutics Inc (MAZE)’s Day in Review: Closing at 9.25, Up by 5.23 - DWinneX

May 01, 2025
pulisher
Apr 30, 2025

Maze Therapeutics (NASDAQ:MAZE) versus Vaxcyte (NASDAQ:PCVX) Financial Survey - Defense World

Apr 30, 2025
pulisher
Apr 25, 2025

Maze Therapeutics (NASDAQ:MAZE) Shares Down 19.4% – Here’s What Happened - Defense World

Apr 25, 2025
pulisher
Apr 11, 2025

Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 11, 2025
pulisher
Apr 08, 2025

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Apr 08, 2025
pulisher
Apr 04, 2025

Guggenheim Reiterates Buy Rating for Maze Therapeutics (NASDAQ:MAZE) - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Leerink Partnrs Has Bearish Forecast for MAZE Q1 Earnings - Defense World

Apr 04, 2025
pulisher
Mar 31, 2025

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Maze Therapeutics Turns Profitable: $52M Net Income as Clinical Trials Progress - Stock Titan

Mar 31, 2025
pulisher
Mar 26, 2025

Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (NASDAQ:MAZE) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 20, 2025

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 20, 2025
pulisher
Mar 17, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 17, 2025
pulisher
Mar 05, 2025

Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Quiet Period To End on March 12th - Defense World

Mar 05, 2025
pulisher
Mar 01, 2025

Leerink Partners Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.6%Still a Buy? - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Guggenheim Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Leerink Partnrs - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

FY2024 Earnings Forecast for MAZE Issued By Leerink Partnrs - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Maze Therapeutics (NASDAQ:MAZE) Upgraded at TD Cowen - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

FY2024 Earnings Estimate for MAZE Issued By Leerink Partnrs - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at JPMorgan Chase & Co. - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at Guggenheim - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Maze Therapeutics (NASDAQ:MAZE) Raised to “Strong-Buy” at Leerink Partnrs - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Maze Therapeutics initiated with a Buy at TD Cowen - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Leerink Partners - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829 - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

Cowen initiates Maze Therapeutics stock with Buy rating By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 25, 2025

Maze Therapeutics receives positive ratings following recent IPO - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 25, 2025
pulisher
Feb 25, 2025

Guggenheim sets $19 target on Maze Therapeutics stock By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 25, 2025

Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target -February 25, 2025 at 06:43 am EST - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target -February 25, 2025 at 06:32 am EST - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

Maze Therapeutics initiated with an Outperform at Leerink - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

JPMorgan sets Maze Therapeutics stock to Overweight with $30 target By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 22, 2025

This New Drug Mimics The Health Effects of Living at High Altitude - ScienceAlert

Feb 22, 2025
pulisher
Feb 18, 2025

Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month LowShould You Sell? - MarketBeat

Feb 18, 2025

Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)

Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):